Scarica l'app Stockscreener
3.51
0.57%
0.02
Lisata Therapeutics Inc Borsa (LSTA) Ultime notizie
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA) - marketscreener.com
Lisata Therapeutics (LSTA) Rises 2.3% as Stock Tests Key ResistanceHigh Conviction Picks - newsline.com
LSTA Rallies 2.3% to $3.56 as Support Holds Ahead of ResistanceDip Buy Trade - newsline.com
LSTA Q3 2025 Earnings: EPS Beat Exceeds Expectations as Clinical Progress ContinuesQuarterly Financial Update - newsline.com
Lisata shares nearly double on buyout offer: Here are the details - MSN
Kuva Labs Agrees to Acquire Lisata Therapeutics for Four Dollars Per Share - HarianBasis.co
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share - Yahoo Finance
Kuva Labs launches $4/share tender offer to acquire Lisata Therapeutics, plus potential $3/share milestone payments. - Pluang
Lisata Therapeutics (NASDAQ: LSTA) to be acquired for $4.00 cash plus CVRs - Stock Titan
Kuva Labs subsidiary offers $4.00 plus CVR to acquire Lisata (LSTA) - Stock Titan
Press Release: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc. - Moomoo
LSTA SEC FilingsLisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
LSTA Q3 2025 Earnings: Narrower Loss Surpasses Estimates as Clinical Progress ContinuesCFO Commentary Report - newsline.com
Lisata Therapeutics, Inc. Announces Amendment and Waiver to Merger Agreement with Kuva Labs Inc. and Kuva Acquisition Corp – Minichart - Minichart
Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline - TipRanks
Lisata Extends Kuva Labs Merger Timeline; Outside Date to July 17, $1.5 Million Option to Aug 17 - TradingView
Lisata Therapeutics (LSTA) extends Kuva Labs tender offer deadlines and adds $1.5M extension fee - Stock Titan
LSTA Q3 2025 Earnings: EPS Surpasses Estimates Despite Lack of Revenue, Stock Edges LowerRetail Earnings Report - newsline.com
LSTA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lisata Therapeutics (LSTA) Holds Steady at $3.37 as Key Levels NarrowPCR Spike - newsline.com
Lisata Therapeutics (LSTA) Eases Amid Modest Pullback — Key Support Levels in FocusMoving Average Crossovers - newsline.com
LSTA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com
Lisata Therapeutics (LSTA) Files 8-K on Proposed Acquisition and Tender Offer – Key Information for NASDAQ Investors - Minichart
Kuva to seek Lisata tender offer (LSTA) under March 6, 2026 merger - Stock Titan
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing - Investing.com UK
Lisata Therapeutics Faces Uncertainty in Kuva Tender Offer - TipRanks
Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing - Stock Titan
Lisata Therapeutics Announces Amendment to Merger Agreement with Kuva Labs and Contingent Value Rights Agreement - Minichart
LSTA Q3 2025 Earnings: Narrower-Than-Expected Loss Marks Progress in Clinical-Stage BiotechRevenue Growth Outlook - The Legal Advocate
What are the Core Details of the Kuva Labs Acquisition of Lisata Therapeutics - Kavout
Stocks to Watch: Oculis, Lisata, Healthy Choice Wellness - Moomoo
Lisata Therapeutics Revises Merger Terms, Adds Milestone CVRs - TipRanks
Lisata Therapeutics (LSTA) preliminary tender-offer communication; merger dated March 6, 2026 - Stock Titan
Lisata Therapeuticsamends merger offer price to $4 per share plus CVR - marketscreener.com
Lisata Agrees to $4 Cash Plus Up to $3 CVR in Amended Kuva Tender Offer - TradingView
Lisata (NASDAQ: LSTA) cuts cash to $4, lifts CVR upside to $3 - Stock Titan
LSTA Technical Analysis | Trend, Signals & Chart Patterns | LISATA THERAPEUTICS INC (NASDAQ:LSTA) - ChartMill
Lisata Therapeutics (LSTA) Q3 2025 Earnings: EPS Beat Drives Positive Stock ReactionSubscription Growth Report - The Legal Advocate
Lisata, Mobileye, VF, Canada Goose, F5 Trending With Analysts - TipRanks
Lisata Therapeutics (LSTA) Holds Steady at $3.14 as Range-Bound Trading PersistsLow Volume Node - The Legal Advocate
Lisata Therapeutics (LSTA) Delivers Q3 2025 Beat — EPS $-0.49 vs $-0.55 ExpectedFinancial Summary - Newser
H.C. Wainwright Maintains Lisata Therapeutics(LSTA.US) With Hold Rating - Moomoo
Lisata Therapeutics (LSTA) Climbs +2.92% — Resistance at $3.33 in Focus 2026-05-17Stock Analysis - Newser
LSTA Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
HC Wainwright Downgrades Lisata Therapeutics to Neutral From Buy - marketscreener.com
H.C. Wainwright downgrades Lisata Therapeutics stock rating to neutral By Investing.com - Investing.com Australia
H.C. Wainwright downgrades Lisata Therapeutics stock rating to neutral - Investing.com
H.C. Wainwright Downgrades Lisata Therapeutics(LSTA.US) to Hold Rating - Moomoo
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA) - GlobeNewswire Inc.
Kuva to acquire Lisata (NASDAQ: LSTA) for $5.00 plus $1.00 CVR - Stock Titan
Number of shareholders of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
6.83%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):